Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 7/20 | 0.52 |
| ▸ | WNT3A | P56704 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794489 | 0.92 | NPC1 (0.59) | KDM4ECTNNB1WNT3ANPC1RAB9A | |
| SCHEMBL6794849 | 0.82 | CTNNB1 (0.48) | KDM4ECTNNB1WNT3ANPC1RAB9A | |
| SCHEMBL13382573 | 0.78 | CTNNB1 (0.50) | KDM4ECTNNB1WNT3ANPC1RAB9A | |
| SCHEMBL2800434 | 0.76 | MAPT (0.55) | KDM4ECTNNB1WNT3ANPC1RAB9A | |
| SCHEMBL2254197 | 0.76 | CTNNB1 (0.53) | KDM4ECTNNB1WNT3ANPC1RAB9A | |
| SCHEMBL21917869 | 0.76 | RAB9A (0.54) | KDM4ECTNNB1WNT3ANPC1RAB9A | |
| SCHEMBL14592085 | 0.74 | MEN1 (0.48) | KDM4ENPC1RAB9AMAPTMEN1 | |
| SCHEMBL5199273 | 0.74 | GRM5 (0.55) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL6177854 | 0.74 | NPC1 (0.57) | KDM4ENPC1RAB9AMAPTMEN1 | |
| SCHEMBL1516344 | 0.74 | NPC1 (0.83) | KDM4ECTNNB1WNT3ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612094-B2 | Tri-substituted heteroaryls and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2009-11-03 | — | — | US | disclosed |
| EP-1542994-B1 | NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | PFIZER PROD INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20080275235-A1 | NOVEL FUSED HETEROAROMATIC COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-7417041-B2 | Imidazopyrimidines as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7273936-B2 | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMITHKLINE BEECHAM CORPORATION | 2006-11-02 | — | — | US | disclosed |
| US-20060063809-A1 | Tri-substituted heteroaryls and methods of making and using the same | BIOGEN MA INC. | 2006-03-23 | — | — | US | disclosed |
| EP-1601676-A2 | FUSED IMIDAZOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | Pfizer Products Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| CN-1658866-A | Tri-substituted heteroaryls and methods of making and using the same | BIOGEN INC (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-1499308-A2 | TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2004078110-A2 | FUSED IMIZADOLES AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040176390-A1 | Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-09-09 | — | — | US | disclosed |
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2003087304-A2 | TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030166633-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-09-04 | — | — | US | disclosed |
| EP-1257543-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM PLC (GB) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001062756-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, TGFBR2, SMAD3 | KDM4E 2073/4885CTNNB1 655/4885WNT3A 1676/4885 |
| US-20060063809-A1 | Tri-substituted heteroaryls and methods of making and using the same | ALK, ACVR1, ACVRL1 | KDM4E 51/4885CTNNB1 1095/4885WNT3A 1025/4885 |
| US-20060247233-A1 | Thiazoles inhibitors of the alk-5 receptor | SMAD3, ALK, SMAD2 | KDM4E 1369/4885CTNNB1 671/4885WNT3A 1069/4885 |
| US-20030166633-A1 | Pyridinylimidazoles | NR0B1, NR1I2, NR0B2 | KDM4E 3032/4885CTNNB1 2319/4885WNT3A 2539/4885 |
| US-20080275235-A1 | NOVEL FUSED HETEROAROMATIC COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | TGFBR1, SMAD3, SMAD2 | KDM4E 1485/4885CTNNB1 318/4885WNT3A 1253/4885 |
| US-20040176390-A1 | Novel fused heteroaromatic compounds as transforming growth factor (TGF) inhibitors | SMAD3, TGFBR1, SMAD2 | KDM4E 1697/4885CTNNB1 500/4885WNT3A 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.